[company_age]18.0[/company_age][employees]11-50 employees[/employees][funding]Series D[/funding][description]Xeltis is a revolutionary medical technology company pioneering the field of Endogenous Tissue Restoration (ETR). Their groundbreaking approach involves developing artificial vascular implants that are gradually replaced by the patient's own living tissue, eliminating the need for repeated surgeries and reducing the risk of complications. This technology, based on Nobel Prize-winning breakthroughs in polymer science, sets Xeltis apart from traditional vascular implant manufacturers. Their commitment to improving patient outcomes through self-healing, non-immunogenic implants positions them as a leader in the vascular surgery landscape.[/description][ps]Artificial vascular implants and valves.[/ps]